期刊
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
卷 17, 期 3, 页码 275-285出版社
WILEY
DOI: 10.1111/ddg.13773
关键词
-
类别
资金
- Wilhelm Sander Stiftung [2011.066.1]
- Deutsche Forschungsgemeinschaft [FE 1282/2-1]
- Wilhelm-San-der-Stiftung [2012.077.1]
- Helmholtz Alliance for Immunotherapy of Cancer
Background and objectives : Primary cutaneous diffuse large B-cell lymphoma, NOS (PCLBCL/NOS) is a rare PCLBCL. Only few data are available for this tumor. The aim of this study was to identify clinical and/or immunohistochemical markers (in addition to Bcl-2) that characterize PCLBCL/NOS, assist in differentiating it from PCLBCL, leg type (PCLBCL/LT) and help to assess the clinical course/prognosis. Patients and methods : Bcl-2 -PCLBCL/NOS) cases (n = 14 were compared with Bcl-2(+) PCLBCL/LT cases (n = 29). Results : PCLBCL/NOS patients were younger, predominantly male and had better survival rates than patients with PCLBCL/LT. Patients with PCLBCL/NOS presented more often with larger plaques limited to one or two contiguous body regions, whereas PCLBCL/LT cases often presented with disseminated lesions. Neoplastic cells had a higher proliferation rate (Ki67) in PCLBCL/LT patients. The tumor microenvironment of PCLBCL/NOS had a more prominent CD3 + infiltrate. Overall survival data for the whole cohort (n = 37) revealed that female gender and Bcl-2 expression correlated with a worse survival rate. Bcl-6 expression and centroblastic subtype correlated with better outcomes. None of the other markers studied (e. g. GCB/non-GCB subtype) correlated with survival rate. Conclusions : PCLBCL/NOS and PCLBCL/LT differ in their clinical behavior and outcomes. Bcl-2 still seems to be the best marker for discriminating between these two subgroups. Bcl-2, female gender and Bcl-6 represent prognostic markers for PCLBCL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据